Latest Investment Funds stories from Money.
The London-based investment firm Schroders is reportedly looking to withdraw from the China mutual funds sector, coinciding with its impending acquisition by US asset manager Nuveen in a significant £10bn transaction.
Pension and sovereign wealth funds express frustration over soaring legal expenses from leading law firms, advocating for a cost-sharing approach with buyout groups.
This analysis explores whether the SCHB Total Stock Market ETF or the VTV Value ETF presents a more favorable option for investors in the current market landscape.
WisdomTree has launched a new exchange-traded fund (ETF) aimed at rare earth elements and metals, responding to the increasing global demand for these essential resources.
The Institutional Limited Partners Association (ILPA) has expressed worries about the emergence of 'conflict vehicles' in the private equity sector, driven by continuation vehicles and a surge in retail investment.
For dividend investors aiming for broad diversification, this ETF may be worth considering. It offers a range of options to enhance investment strategies.
As geopolitical tensions escalate, there is potential for gold mining ETFs to reach new heights, reflecting the market's response to instability.
Strategic angle: Discover how this Vanguard ETF offers hedge fund-like benefits without the associated costs.
Strategic angle: An analysis of the VanEck ETF's focus on rare earth and strategic metals amidst market volatility.
Strategic angle: A look at how increasing sovereign demand for minerals is positively impacting a specific metals and mining ETF.
Strategic angle: Exploring the potential of the URNM ETF in the uranium sector.
Strategic angle: Exploring the exploitation of elderly individuals by private equity firms.
Strategic angle: The Middle East war has introduced a new layer of uncertainty for Asia-focused private equity managers already navigating a multiyear fundraising slump.
Strategic angle: Discover the top-performing ETF that significantly increased investment returns over the last decade.
Strategic angle: An analysis of Vanguard Growth's performance against other ETFs.
Strategic angle: DAFNA Capital has made adjustments to its holdings in the iShares Biotechnology ETF as part of a broader strategy in the biotech sector.
Strategic angle: Explore the implications of a significant investment by a hedge fund in Immunovant and what it could mean for potential investors.
Recent findings suggest that while private equity is driving investment in primary care, clinician growth is tempered by a notable increase in exits.